dreamshark: (Default)
[personal profile] dreamshark
As I have commented before, a policy of endless boosters of the original vaccines at constantly decreasing intervals is not a viable long term strategy for combatting the evolving coronavirus. It might be worth pursuing as a short-term crisis response targeted to vulnerable people, but more data is desperately needed. And of course what we really need is those next-gen vaccines that are reportedly under development now. Here's some good news on both fronts.

I just found this article about a study that NIAID is sponsoring at the University of Rochester that will both evaluate the efficacy of booster #2 and (more excitingly) fold in trials of "new investigational vaccines that target the Beta, Delta, and Omicron variants." 
This account has disabled anonymous posting.
(will be screened if not validated)
If you don't have an account you can create one now.
HTML doesn't work in the subject.
More info about formatting

If you are unable to use this captcha for any reason, please contact us by email at support@dreamwidth.org

Profile

dreamshark: (Default)
dreamshark
May 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 2025

Style Credit